Abbott agrees to pay about $385 million over alleged WIC and Medicaid product-quality misrepresentations
Oct 4, 2026 edition · GC-2026-0105 · Published 2026-10-04 · Version 2 · Settled
Abbott's settlement provides approximately $385 million plus interest to resolve disputed WIC and Medicaid product-quality claims, with express denials and reserved claims.
What happened
A September 2026 settlement agreement provides for Abbott to pay $384,999,040.12 plus interest in connection with disputed claims involving powdered infant formula and nutritional products. The government contends that, from January 2018 through December 2022, Abbott failed to comply with federal and state manufacturing obligations at its Sturgis, Michigan and Casa Grande, Arizona facilities and misrepresented compliance to WIC and Medicaid programs. The agreement is a compromise, not an admission of facts or liability. Abbott denies the allegations, and the United States does not concede that its claims lack merit. DOJ announced the resolution September 14; this tracked event date is an announcement date, not proof of the agreement’s last-signature effective date.
The payment provisions separate $348,700,868 for the United States, $35,491,288.40 for participating Medicaid states and $806,883.72 for Massachusetts's supplemental WIC appropriation, with specified interest terms. The agreement conditions relevant releases on receipt of payment and reserves categories including criminal liability, certain administrative enforcement, individual liability and conduct outside the defined covered conduct. It also addresses unallowable settlement-related costs previously claimed from federal programs. Its effective date is the date of the last signature, rather than an assumption that every payment or release occurred when one government representative signed. These terms connect manufacturing compliance representations to government-program claims while keeping the settlement's scope and unresolved rights intact.
Scope and timing
- Authority status
- Settled
- Applicability
- Operationally relevant
- Audience
- Health systems, Provider networks
- Jurisdiction
- Federal, California
Why it matters
Government-program suppliers need traceable support for product-quality and eligibility representations, including when manufacturing deviations may undermine continued claims or rebates.
Recommended action
Map program and contract quality representations to manufacturing evidence and escalation records. Review continued submissions after deviations, settlement-cost allowability where applicable, and the exact scope of any release with counsel.
Case details
- agencies
- U.S. Department of Justice, U.S. Department of Agriculture, HHS Office of Inspector General, State Medicaid programs
- entities
- Abbott Laboratories
- action Type
- Settlement
- event Date
- 2026-09-14
- alleged Conduct
- Alleged failure to manufacture covered formula and nutritional products in compliance with requirements and alleged misrepresentations to WIC and Medicaid programs. Abbott denied the allegations.
- resolution
- Payment of $384,999,040.12 plus interest, with federal, Medicaid state, and Massachusetts allocations.
Operational lessons
- Product-quality deviations can create payment-integrity exposure.
- Program eligibility representations need continuing support.
- Unallowable settlement costs must be separated from government-program claims and cost reporting.
Related coverage
The resolution includes participating state Medicaid payments and supplier representation controls. Medicare & Medicaid →
Sources
- Abbott False Claims Act Settlement AgreementOfficial · U.S. Department of Justice · Source review 2026-09-20
- Official retained source documentOfficial · Official issuing agency · 2026-09-14 · Source review 2026-10-16
Complete edition and supplemental material
This finding in the complete approved report →Regulatory horizons, CIA trends and implementation trackers remain in the full report.
Read the entire Enforcement Briefing report →